Country: United States
Language: English
Source: NLM (National Library of Medicine)
ALOSETRON HYDROCHLORIDE (UNII: 2F5R1A46YW) (ALOSETRON - UNII:13Z9HTH115)
Lifestar Pharma LLC
ORAL
PRESCRIPTION DRUG
Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: - chronic IBS symptoms (generally lasting 6 months or longer), - had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and - not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: - frequent and severe abdominal pain/discomfort, - frequent bowel urgency or fecal incontinence, - disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men. Alosetron tablets should not be initiated in patients with constipation [see Warnings and Precautions (5.1)] . Alosetron tablets are co
Alosetron Tablets USP, 0.5 mg (0.562 mg alosetron HCl equivalent to 0.5 mg alosetron), are round, film coated, white colored biconvex tablets debossed with "LS 702" on one side and plain on other side. Bottles of 30 (NDC 70756-702-30) with child-resistant closures. Alosetron Tablets USP, 1 mg (1.124 mg alosetron HCl equivalent to 1 mg alosetron), are round, film coated, blue colored biconvex tablets debossed with "LS 701" on one side and plain on other side. Bottles of 30 (NDC 70756-701-30) with child-resistant closures. Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature). Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Abbreviated New Drug Application
Lifestar Pharma LLC ---------- MEDICATION GUIDE Alosetron (a-LOE-se-tron) Tablets, USP Read the Medication Guide you get with each refill for alosetron tablets. There may be new information. This Medication Guide does not take the place of talking with your doctor. What is the most important information I should know about alosetron tablets? Alosetron tablets is a medicine only for some women with severe chronic irritable bowel syndrome (IBS) whose: ● main problem is diarrhea and ● IBS symptoms have not been helped enough by other treatments. Some people have developed serious bowel side effects while taking alosetron tablets. Serious bowel (intestine) side effects can happen suddenly, including the following: ● Serious complications of constipation: These complications may lead to a hospital stay and, in rare cases, blood transfusions, surgery, and death. People who are older, who are weak from illness, or who take other constipating medicines may be more likely to have serious complications of constipation with alosetron tablets. ● To lower your chances of getting serious complications of constipation, do the following: ○ If you are constipated, do not start taking alosetron tablets ○ If you get constipated while taking alosetron tablets, stop taking it right away and call your doctor. ○ If your constipation does not get better after stopping alosetron tablets, call your doctor again. ○ If you stopped taking alosetron tablets, do not start taking alosetron tablets again unless your doctor tells you to do so. ● Inflammation and injury of the intestines caused by reduced blood flow (ischemic colitis: Ischemic colitis is caused by reduced blood flow to parts of the large bowel. The chance of getting ischemic colitis when you take alosetron tablets for more than 6 months is not known. Ischemic colitis may lead to a hospital stay and, in rare cases, blood transfusions, surgery, and death. Stop taking alosetron tablets and call your doctor or get medical help if you have symptoms of ischemic colitis Read the complete document
ALOSETRON - ALOSETRON TABLET LIFESTAR PHARMA LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ALOSETRON TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ALOSETRON TABLETS. ALOSETRON TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2000 WARNING: SERIOUS GASTROINTESTINAL ADVERSE REACTIONS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ INFREQUENT BUT SERIOUS GASTROINTESTINAL ADVERSE REACTIONS HAVE BEEN REPORTED WITH THE USE OF ALOSETRON TABLETS. THESE EVENTS, INCLUDING ISCHEMIC COLITIS AND SERIOUS COMPLICATIONS OF CONSTIPATION, HAVE RESULTED IN HOSPITALIZATION AND, RARELY, BLOOD TRANSFUSION, SURGERY, AND DEATH. ALOSETRON TABLETS ARE INDICATED ONLY FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS) WHO HAVE NOT RESPONDED ADEQUATELY TO CONVENTIONAL THERAPY. (1) DISCONTINUE ALOSETRON TABLETS IMMEDIATELY IN PATIENTS WHO DEVELOP CONSTIPATION OR SYMPTOMS OF ISCHEMIC COLITIS. DO NOT RESUME ALOSETRON TABLETS IN PATIENTS WHO DEVELOP ISCHEMIC COLITIS. (2.1, 5.1, 5.2) INDICATIONS AND USAGE Alosetron tablets are selective serotonin 5-HT antagonist indicated only for women with severe diarrhea- predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded and not responded adequately to conventional therapy. (1) Severe IBS includes diarrhea and 1 or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. (1) DOSAGE AND ADMINISTRATION Starting dose is 0.5 mg twice a day (2.1) May increase dose to 1 mg twice a day after 4 weeks if starting dosage is well tolerated but does not adequately control IBS symptoms (2.1) Discontinue alosetron tablets in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day. (2.1) DO Read the complete document